Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans.
Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected …

that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently
licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses 12 …

Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …

There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the
ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. …

Several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …

The SARS-CoV-2 B. 1.617. 2 Delta variant of concern (VOC) continues to drive a sharp increase
in COVID-19 cases in the UK, with a current doubling time of 3· 5–16 days, 1 consistent …

Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …

Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination
programs globally, which includes administration of mRNA vaccines. Cytokine release …

We sought to compare neutralising antibody responses between seronaive haemodialysis
patients and the healthy individuals we have already reported on as part of the Legacy study. …

We previously identified the function of the hepatitis C virus (HCV) p7 protein as an ion
channel in artificial lipid bilayers and demonstrated that this in vitro activity is inhibited by …